net dbt
market pressur hit off-set visibl lack
walgreen culmin challeng face compani
industri highlight reimburs pressur like acceler start
year view combin intensifi reimburs pressur weak
front end growth variou move piec drug price off-set sg
benefit includ increas save guidanc transform program
addit ebit/ep like remain significantli constrain next three
year weak fundament exacerb non-oper item like higher tax
rate lower share repurchas vs previou estim trend driven
gross margin lower remain place believ on-going shift pbm
contract notabl rebat debat could lead addit reimburs pressur
walgreen recent announc partnership could help time short-term
well see potenti benefit outsid scope drive near-term valu
share result reiter under-perform rate lower po
reduc target multipl price-to-earnings
estim reduc cost cut alreadi model
reduc ep ep
biggest driver reduct step-down us retail gm
assumpt lower share repurchas higher interest expense/tax rate
assumpt secondari factor also moder sg cut given
expect step-up bonu accrual biggest swing factor estim
would better partnership contribut addit sg below-the-lin cut
upcom event catalyst
key focu investor gain increment comfort around scope
reimburs pressur back half year addit commentary/
announc around scope financi contribut recent struck
partnership increas labcorp roll-out increas deliveri
biggest near-term opportun view separ addit prefer part
relationship file buy could act catalyst share
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
walgreen follow complet rite
aid store acquisit largest global
pharmaci nearli store us
alon compani also oper intern
pharmaci busi primarili compos
boot pharmaci unit kingdom
allianc healthcar intern wholesal
distributor pharmaceut medic
product europ walgreen headquart
under-perform rate predic
pressur competit dynam
potenti increment competit
amazon small step market core
profit dollar growth slow think limit
visibl creat challeng near-term
stock perform view range-bound
increas reimburs pressur combin lower brand inflat
walgreen exist prioriti lead consist growth futur
opportun off-set reimburs pressur weaken
lower brand inflat slower gener deflat
updat guidanc flat y/i
impact gross margin due faster grow specialti busi
pharmaci sale organ
expect gross margin remain pressur unlik
improv short-term
volum us pharmaci retail perform plan
estim bonu pay-out year substanti reduc
lap continu see advers
reimburs pressur impact revenu line
currenc impact ep unchang
project tax rate includ non-discret benefit
chang geograph earn
increas cost save target least
consult suppli chain cost second quartil
reduct boot central workforc
digit opportun reduc cash spend
equal split opex capital-expenditure
expect adjust ep broadli flat impact
tax rate increas creat headwind
depend year
reorgan magnitud save execut
goal drive pharmaci front end sale
invest year boost digit
reimburs rate cut come specif payers/pbm
across board investor expect acceler pressur
run-rat quarter investor expect
heavi quarter reimburs pressur
dont expect norm move forward
fep reduct
saw medicar part
plan similar level reimburs next year
lower level gener util project
start year materi impact revenu
cost line
expect reimburs pressur subsid
expect gener util increas cours year
compani price power
want work partner like
gener util script growth
lost major aetna book busi anniversaryd
lost busi
becam prefer
back market growth part
share buyback rational chang
start buy back share next day
expect repurchas year
expect percentag point growth share repurchas
flow ex-rad benefit provid guidanc
headwind year
compani deliv cash flow annual
headwind
manag increas cash tax y/i
cycl legal payout relat
capital-expenditure run-rat due convers
store
see normal level
technolog side investor think chang rebat rule
system place today
would make sens walgreen buy thing would
acceler wba strategi perspect
open kind partnership make sens
price object base ep
multipl five-year averag absolut basi around discount
five-year averag reflect view walgreen core retail pharmaci busi
long-term structur pressur must diversifi stabl busi line
improv growth outlook
upsid risk better expect gener save new partnership
healthcar area labcorp etc support long-
term growth addit volum econdisc/rit aid contribut
addit new partnership faster expect growth prime therapeut
relationship downsid risk po on-going price reimburs pressur
higher prescript attrit part relationship integr risk
risk amazon anoth disrupt forc enter suppli chain market
lack available/app attract capit deploy opportun
michael cherni herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
